| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Alcon Research |
| Information provided by: | Alcon Research |
| ClinicalTrials.gov Identifier: | NCT00058994 |
Purpose
The purpose of this study is to demonstrate that anecortave acetate is superior to placebo in maintenance of visual acuity at the 12- and 24-month visits.
| Condition | Intervention | Phase |
|
Macular Degeneration Maculopathy, Age-Related |
Drug: anecortave acetate |
Phase III |
| Genetics Home Reference related topics: | X-linked juvenile retinoschisis |
| MedlinePlus related topics: | Macular Degeneration |
| ChemIDplus related topics: | Anecortave acetate |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal Choroidal Neovascularization Due to Exudative Age-Related Macular Degeneration |
Eligibility
| Ages Eligible for Study: | 50 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Patients at least 50 years of age, of any race, and either sex with a clinical diagnosis of exudative AMD and a primary or recurrent subfoveal CNV lesion in the study eye.
Contacts and Locations More Information
| Study ID Numbers: | C-02-29 |
| First Received: | April 15, 2003 |
| Last Updated: | August 4, 2008 |
| ClinicalTrials.gov Identifier: | NCT00058994 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
|
